Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Mol Cancer Res. 2019 Mar 25;17(6):1279–1293. doi: 10.1158/1541-7786.MCR-18-1355

Figure 6. Trametinib treatment prevents the migration and invasion of TP63 knockdown HNSCC cell lines.

Figure 6.

P-ERK1/2, T-ERK1/2, P-STAT3 (Tyr705), P-STA3 (Ser 727), and T-STAT3 protein levels were analyzed in (A) FaDu-TP63 shRNA3 cells or (B) CAL27-TP63 shRNA3 cells treated with DMSO (vehicle) or 10 μM Trametinib by western blotting. (C-F) Effects of Trametinib treatment on migration of FaDu-TP63 shRNA3 and CAL27-TP63 shRNA3 cells were measured using scratch assay, and the percentage closure was quantified (two-tailed unpaired Student t-test, **: P < 0.01; Mean ± SD). (G, H) Effects of Trametinib treatment on invasion of FaDu-TP63 shRNA3 and CAL27-TP63 shRNA3 cells was measured using matrigel-coated transwell inserts, and the number of cells invaded/field was quantified (two-tailed unpaired Student t-test, **: P < 0.01; Mean ± SD).